Ziopharm Oncology, Inc.

Epix Pharmaceuticals, Inc.

Epix Medical, Inc.

Catalyst Medical

Factor 1a, LLC

John C Amedio, Jr

Peter Caravan

Frank Walter Waligora

Barbara P Wallner

Andrew Kolodziej

Thomas J McMurry

Stephane A Dumas

Zhaoda Zhang

Philip B Komarnitsky

Vincent Jacques

Steffi K Koerner

Wei-Chuan Sun

Kevin Zhou

Stuart Levy

Mark Fountain

Paul J Bernard

Xifang Wang

Alexander L Nivorozhkin

Shrikumar Nair

Matthew Greenfield

Shirley Kalogeropoulos

Peter D Caravan

Disclosed herein are crystalline compounds of formula (I) 

Salts of isophosphoramide mustard and analogs thereof

Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups; and Ais an ammonium cation.

Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups and Ais an ammonium cation.

Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.

Optically pure and enriched isomers of chelating ligands and contrast agents

Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Peptide-based multimeric targeted contrast agents

A process for preparing a phosphodiester of the formula: ##STR1## is described that involves (1) reaction of a first alcohol with phosphorous trichloride to form a phosphorodichlorodite, (2) reaction of the phosphorodichlorodite with an amine to form a phosphorodiamidite, (3) reaction with a second alcohol (which may be the same as the first alcohol) to form a phosphoramidite diester, and finally, (4) hydrolysis and oxidation of the phosphoramidite to form the phosphodiester. R and R1 may represent aliphatic, aromatic, heterocyclic, peptidic, peptoid, deoxyribo- or ribonucleotidic or nucleosidic, or organic chelating moieties.

Process for synthesizing phosphodiesters

Growing community of inventors

Franklin, MA, United States of America

John C Amedio, Jr